SECENDS - VRTX

2025

Q4 2 filings

Nov 4

Q3 2025 Results

Unable to extract revenue and EPS figures from provided XBRL data

10-Q View →

Nov 3

Q3 2025 Earnings Released

Revenue $[insert revenue], EPS $[insert EPS]

8-K View →

Q3 2 filings

Aug 5

Q2 2025 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q View →

Aug 4

Q2 Earnings + CSO Retirement

David Altshuler CSO retiring Aug 2026

8-K View →

Q2 5 filings

May 19

Share Repurchase Program

$4B new buyback authorized, $4.775B total capacity

8-K View →

May 14

Annual Shareholder Meeting

11 directors elected, Ernst & Young ratified as auditor

8-K View →

May 6

Q1 2025 Results

Unable to extract revenue and EPS data from provided content

10-Q View →

May 5

Q1 2025 Earnings

Q1 2025 financial results reported May 5, 2025

8-K View →

Apr 3

2024 Proxy Statement

Annual meeting: May 14, 2025 (virtual), Record date: March 17, 2025

DEF 14A View →

Q1 3 filings

Mar 28

VX-264 Program Discontinued

$400M impairment charge for Q1 2025

8-K View →

Feb 13

FY24 2024 Results

Data insufficient - revenue and EPS figures not extractable from provided XBRL tags

📌 Data insufficient - specific operational milestones not extractable from provided XBRL metadata

10-K View →

Feb 10

Q4 Earnings + COO Change

Stuart Arbuckle COO retires July 1, CFO Wagner adds COO role

8-K View →

2024

Q4 3 filings

Dec 20

FDA Approves ALYFTREK

ALYFTREK approved for cystic fibrosis, priced at $370,269 annually

8-K View →

Nov 5

Q3 2024 Results

Financial data not available in provided XBRL extract

10-Q View →

Nov 4

Q3 Earnings

Q3 2024 financial results reported

8-K View →

Q3 3 filings

Aug 16

Headquarters Lease Extension

1.1M sq ft lease extended to June 2044

8-K View →

Aug 2

Q2 2024 Results

Unable to extract revenue and EPS figures from provided XBRL data structure

10-Q View →

Aug 1

Q2 Earnings

Q2 2024 financial results reported

8-K View →

Q2 7 filings

Jun 27

Alpine Acquisition Accounting Impact

$4.4B AIPR&D expense from $5B Alpine acquisition

8-K View →

May 20

Acquired Alpine Immune Sciences

$5.0B equity value deal completed

8-K View →

May 15

Annual Shareholder Meeting

11 directors elected, auditor ratified, exec comp approved

8-K View →

May 7

Q1 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

10-Q View →

May 6

Q1 2024 Earnings

Q1 2024 financial results reported

8-K View →

Apr 11

Acquired Alpine Immune Sciences

$65/share cash tender offer

8-K View →

Apr 4

2024 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: Advisory vote scheduled

DEF 14A View →

Q1 2 filings

Feb 15

FY 2023 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

📌 Unable to identify specific milestone from provided XBRL data format

10-K View →

Feb 5

Q4 2023 Earnings

Q4 and full year 2023 financial results reported

8-K View →

2023

Q4 3 filings

Dec 8

FDA Approves CASGEVY

Gene therapy for sickle cell disease, $2.2M wholesale price

8-K View →

Dec 5

Nancy Thornberry Appointed to Board

Board expanded from 10 to 11 members, $400K RSU grant

8-K View →

Nov 7

Q3 2023 Results

Financial figures not available in provided excerpt

10-Q View →